Park Medi World Ltd Q1 FY27 Earnings Call Summary

Event Participants

Executives

4
Ankit Gupta, Rajesh Sharma, Sanjay Sharma, Sudesh Sharma

Analysts

9
Akshay Thakur, Anshul Agrawal, Chetan Shah, Kashish Thakur, Nirali Shah, Ronak Agarwal, Sagar Tanna, Shubham Padhiyar, Sumit Gupta

Financials & KPIs

Geographic & Segment Commentary

• Mature Hospitals (Gurgaon, Mohali, Ambala): Growing at a steady 18–20% pace; Mohali has scaled from ₹52 lakhs monthly revenue at acquisition (May 2023) to ₹23 crores, with EBITDA margin trajectory from 12–13% to an expected 26% this year. Gurgaon (Palam Vihar) reached 750 beds with the 100-bed Park Platinum extension.

• New Facilities — Agra & Panchkula: Both commissioned in CY26 (Agra Feb, Panchkula Apr) and ramping in line with expectations; management does not expect any EBITDA loss in these units in FY27, though year-one EBITDA is expected in the 10–12% band versus 20–25% at maturity. Panchkula (350 beds) progressing through NABH accreditation; nine hospitals now have NABH-accredited labs.

• Rudrapur (Medicity Hospital): 330-bed NABH-accredited multi-specialty hospital acquired for ₹177 crores (all-cash), commissioned 22 August 2026 — marking entry into sixth state (Uttarakhand). Pre-acquisition revenue was ₹55–56 crores on 200 beds; target is ₹100 crores revenue, ₹20–22 crores EBITDA, ₹12–13 crores PAT in year one, ramping to ₹140 crores / ₹35–36 crores EBITDA / ₹21–22 crores PAT in FY28. Incremental capex limited to ₹10–12 crores.

• Tricity Cluster (Chandigarh, Mohali, Panchkula, Zirakpur): Densification strategy — will reach ~950 beds by Nov 2026, becoming the largest healthcare provider in the region (350 Panchkula + 150 Mohali addition + 150 Zirakpur). Aimed at capturing upper-North India patient flow (J&K, Himachal, upper UP) en route to Delhi.

Company-Specific & Strategic Commentary

• Capacity Expansion: 1,490 beds being added in CY26 (+46% over CY25's 3,250-bed base); end-FY27 capacity at 4,740 beds and 6,740 beds by FY28, via a further 1,000-bed addition. Total planned capex of ₹767 crores across 2,130 beds over FY27-28 keeps blended capex per bed at ₹36 lakhs.

• Acquisition Pipeline: Two definitive agreements signed in the quarter — Rudrapur (₹177 crores) and Mehar Hospital Zirakpur (150 beds, ₹107 crores); plus 200-bed Narela facility (insolvency acquisition) on track. All three assets (450 beds total) commission in Nov–Dec 2026, funded largely through internal accruals and IPO proceeds without material fresh debt.

• Payer Mix Transformation: Government schemes at 77% of revenue vs 23% self-pay/private insurance/TPA; guiding toward a 70-30 split over next 12–18 months as cash/TPA patients shift from premium providers for affordable high-end care.

• CGHS Rate Benefit: October 2025 rate revision of 12–15% expected to yield 7–7.5% flow-through benefit in FY27, fully visible from Q2 onward as allied government agencies absorb revised rates; management reinvesting benefit into equipment and facility upgrades rather than letting it flow directly to EBITDA.

• Doctor Retention Model: Full-time-dedicated clinician model (no visiting consultants); compensation as top-quartile paymaster, monthly performance bonuses (75th percentile clinical outcome threshold), ESOPs for clinicians/HODs; attritions at consultant level cited as industry-lowest. Management bandwidth maintained via 6–8-month pre-training of second-line leadership in existing hospitals before commissioning new units.

Guidance & Outlook

Risks & Constraints

Q&A Highlights

FY27 Guidance and New-Unit EBITDA Trajectory

• Question: On revenue growth outlook and EBITDA losses at Greenfield units (Panchkula, Agra) — (Anshul Agrawal, Emkay Global)
• Answer: FY27 guidance: revenue ₹2,080 cr (+24%), EBITDA ₹530 cr (+25%), PAT ₹360 cr (+32%). No EBITDA losses expected from new units; year-one EBITDA margins of 10–12% blend with mature hospitals at 30–31% to hold overall 26.5–27% margin. Mature hospitals growing 18–20%. ARPOB guidance at 10–12% band. (Rajesh Sharma / Management)

Rudrapur & Zirakpur Ramp-Up Strategy

• Question: How will Rudrapur ramp up given it's a new state, and how does Zirakpur fit the cluster strategy? — (Anshul Agrawal, Emkay Global)
• Answer: Rudrapur: all 330 beds functional, target ₹100 cr revenue in year one (from ₹55–56 cr pre-acquisition), ₹20–22 cr EBITDA, ₹12–13 cr PAT; FY28 target ₹140 cr revenue. Zirakpur (150 beds) complements Tricity cluster → 950 beds total, making Park the largest provider in the region, capturing patient flow from J&K, Himachal, and upper UP heading to Delhi. First-year target: ₹70–75 cr revenue at 25–26% EBITDA. (Ankit Gupta, MD)

CGHS Rate Revision Impact

• Question: Has the CGHS rate hike flowed into numbers, and when will full impact be seen? Any onco-specific impact like peers? — (Kashish Thakur, Elara Capital)
• Answer: Partial impact visible in Q1; full impact (7–7.5%) from Q2–Q3 as allied government agencies percolate revised rates. No heat felt in oncology segment — strong vendor relationships and negotiated rates have shielded the company; oncology contributes 9–10% of revenue. (Sanjay Sharma, CEO)

CGHS Benefit — EBITDA Retention

• Question: How much of the CGHS rate benefit flows to EBITDA from Q2? — (Sagar Tanna, Alchemie Ventures)
• Answer: The 12–15% hike translates to ~7–7.5% benefit, but it will not directly translate into EBITDA — the company intends to reinvest the opportunity in upgrading equipment, maintenance, and better facilities. However, EBITDA will hold at 26–27% and PAT at 17–18%. (Sanjay Sharma, CEO)

Return on Capital and Management Bandwidth

• Question: Will incremental economics of new beds deteriorate with scale; is management bandwidth a bottleneck for acquisitions? — (Nirali Shah, Ashika Investment Managers)
• Answer: ROIC currently ~18%, expected to rise 150–200 bps in 12–18 months; densification provides durable competitive advantage. Management bandwidth is addressed through continuous training of second-line leadership 6–8 months ahead of each commissioning, ensuring smooth, replicable transitions. (Rajesh Sharma, CFO / Ankit Gupta, MD)

Bed Capacity Guidance Revision and Capex per Bed

• Question: Earlier guidance was 5,040 beds end-FY27; now 4,740 — is Kanpur canceled? Also, acquisition capex per bed (₹70+ lakhs) vs historical ₹34 lakhs — are payback periods extending? — (Shubham Padhiyar, Chhatisgarh Investments)
• Answer: Clarified trajectory: 3,960 at Q1 end → 4,290 post-Rudrapur (Q2) → 4,740 with 450 additional beds in Q3 (Palam Vihar 100, Zirakpur 150, Narela 200 — of which 250 were not in prior communication). FY28: 1,000 more beds → 6,740 total. On capex: blended capex per bed across FY27-28 remains ₹36 lakhs (₹767 cr on 2,130 beds), including acquisitions — Rudrapur's higher per-bed cost is offset by Palam Vihar extension at ₹25 lakhs/bed. (Sanjay Sharma, CEO)

Case Mix Targets and Specialty Breakdown

• Question: What is the target for high-end super-specialty (CONGO) mix over 2–3 years, and share of onco/cardio? — (Sumit Gupta, Antique Stock Broking)
• Answer: High-end mix at 62% (up 440 bps YoY); current revenue split: neuro 14.5%, cardio 12%, urology 11%, oncology 9–10%, joint replacement 9.5%, gastro 7%. No fixed percentage target — mix shifts organically based on regional requirements (e.g., 200-bed onco-dedicated expansion in Ambala, LINAC additions in Bathinda, Rudrapur). Acquired facilities carry similar case mix profiles (~75–80% government scheme, 20–25% cash/TPA). (Ankit Gupta, MD)

Doctor Attrition and Retention

• Question: What is the doctor/HOD attrition rate and retention strategy vs premium competitors? — (Sumit Gupta, Antique Stock Broking)
• Answer: Consultant-level attrition is lowest in the industry. Differentiators: top-quartile pay, performance-linked monthly bonuses for clinicians scoring >75th percentile on patient satisfaction and clinical outcomes, ESOPs for clinicians/HODs, and a no-targets model — doctors are accountable only for outcomes, not revenue. Park's own patient base (~2.5 lakh footfall this quarter) removes dependency on celebrity doctors and supports growth of career-focused clinicians from government medical colleges. (Sanjay Sharma, CEO / Ankit Gupta, MD)

Payer Mix and ARPOB Sustainability

• Question: Current payer mix split, and what ARPOB growth is expected as mix shifts? — (Ronak Agarwal, Ithought PMS)
• Answer: Q1 mix: 77% government schemes, 10% TPA, 13% cash. Expect 70-30 split in next 12–15 months. ARPOB, historically at 3–5%, is now growing at 10–12% and expected to sustain at that level annualized, driven by case-mix shift to super-specialty, payer mix changes, and natural inflation. (Management)

OPD Strategy and Neurology Mix Rationale

• Question: OPD is only 5–6% of mix — what's the strategy to use it as IPD funnel? Also, why is neurology so high? — (Akshay Thakur, Helios Capital)
• Answer: OPD is intentionally not a revenue generator — it functions as a footfall and affordability funnel with 20–25 free/subsidized camps per unit per month and free OPDs on public holidays. High neurology (14.5%) is domain-driven: units located along the Delhi–Chandigarh Grand Trunk Road and Delhi–Jaipur Expressway capture significant trauma and critical cases. (Ankit Gupta, MD)

Key Takeaway

Park Medi World delivered strong Q1 FY27 results — revenue of ₹476 crores (+19% YoY), EBITDA of ₹126 crores (26.5% margin), and PAT of ₹89 crores (+35% YoY) — with earnings growth outpacing revenue on reduced interest costs. The quarter was defined by aggressive yet methodical capacity expansion: 3,960 beds at quarter-end (+32% YoY), two new acquisitions (Rudrapur for ₹177 crores, Zirakpur for ₹107 crores) adding 450 beds, and a 1,490-bed addition planned for CY26 — pushing FY27 capacity to 4,740 beds and 6,740 by FY28. Management guided to FY27 revenue of ₹2,080 crores (+24%), EBITDA of ₹530 crores (+25%), and PAT of ₹360 crores (+32%), with blended capex per bed held at ₹36 lakhs across ₹767 crores of planned spend. Strategy centers on densification (Tricity cluster at ~950 beds), payer-mix shift toward a 70-30 scheme/cash split, and reinvestment of the 7–7.5% CGHS rate benefit into equipment upgrades. Key watch points include occupancy dilution from rapid bed additions, integration of three concurrent commissions in Nov–Dec 2026, and the 2028 promoter-dilution mandate; the company remains fully funded for its growth plan through internal accruals and IPO proceeds without material fresh debt.